Previsão

O preço-alvo médio dos analistas é € 9,75 (+254,55%). A mediana é € 9,97 (+262,55%).

Comprar	17
Manter	4
Vender	0

Notícias Ir para o feed de notícias

CytomX focuses strategy on advanced colorectal cancer after positive Varseta‑M data

CytomX presented early phase‑I data for Varseta‑M in advanced colorectal cancer at the Morgan Stanley Healthcare Conference, showing response rates of 20–30% and an estimated median PFS of 6–7 months. The main adverse event was grade‑3 diarrhea; prophylaxis and dose adjustments reduced severe cases from about 30% to around 10%. The company has pro forma roughly $367 million in cash (runway to at least H2 2028) and is simultaneously advancing a masked interferon‑alfa‑2b program for PD‑1‑refractory melanoma, with first data expected in H1 2025. Next steps include dose selection and regulatory study design under Project Optimus, as well as additional combinations and indication expansions. » Mais em de.investing.com
CytomX reports pipeline progress and prepares registration‑relevant trial for Varseta‑M

CytomX presented positive efficacy data for Varseta‑M in metastatic colorectal cancer at a health conference (ORR 20–30% vs. 1–2% with standard therapy) and emphasized safety‑management improvements, with grade‑3 diarrhea in optimization cohorts falling to about 10%. The company received a $37 million upfront payment from Regeneron, plans a comprehensive data update by the end of 2024, and intends to discuss regulatory strategy with the FDA in 2024. A first registration‑relevant study could start in the first half of 2025; the second lead program, CX‑801, is also expected to deliver initial data in H1 2025. » Mais em de.investing.com
CytomX focuses on EpCAM‑ADC Varseta‑M and reports solid liquidity

CytomX presented its Probody portfolio at the Wells‑Fargo conference with Varseta‑M as the only known EpCAM‑targeting ADC in development, showing encouraging phase‑1 data in metastatic colorectal cancer and an FDA fast‑track designation. The company has more than $350 million in liquid assets, supported by an expanded collaboration with Regeneron. The second program, CX‑801 (masked interferon alfa‑2b), has shown initial biomarker activity in melanomas. Key milestones include additional phase‑1 data by the end of 2024, combination data with bevacizumab in H1 2025, and the planned start of a registrational study for Varseta‑M in H1 2027. » Mais em de.investing.com

Dividendos históricos Dividendos

Todos os indicadores de dividendos Todos os indicadores

Em 2022, CytomX Therapeutics já distribuiu € 0,13 em dividendos. A última distribuição ocorreu em abril de 2022.

Dados financeiros da empresa

No último trimestre, CytomX Therapeutics registou receitas de € 1,24 mi e um ganho líquido de -€ 18,11 mi

(EUR)	junho de 2026	YoY
Receitas	1,24 mi	92,15%
Ganho bruto	1,24 mi	92,15%
Ganho líquido	-18,11 mi	13.759,03%
EBITDA	-17,79 mi	8.292,65%

Dados fundamentais

Métrica	Valor
Capitalização bolsista	€ 620,97 mi
Número de ações	217,7 mi
Máximo/mínimo de 52 semanas	€ 7,12 - € 1,65
Dividendos	Não
Beta	2,14
PER (PE Ratio)	-7,31
PEG (PEG Ratio)	0,05
P/VC (PB Ratio)	2,38
P/V (PS Ratio)	39,13

Perfil da empresa

CytomX Therapeutics, Inc. ist ein auf Onkologie fokussiertes biopharmazeutisches Unternehmen in den Vereinigten Staaten. Das Unternehmen entwickelt auf der Grundlage seiner Probody-Technologieplattform Antikörpertherapeutika für die Behandlung von Krebs. Zu den Produktkandidaten des Unternehmens gehören CX-2009, ein Antikörper-Wirkstoff-Konjugat (ADC) gegen CD166, das sich in klinischen Phase-II-Studien zur Behandlung von Brustkrebs befindet, sowie CX-2029, das sich in klinischen Phase-II-Studien zur Behandlung von nicht-kleinzelligem Plattenepithelkarzinom der Lunge, Plattenepithelkarzinom des Kopfes und Halses, Krebserkrankungen der Speiseröhre und des Magen-Darm-Trakts sowie diffusem großzelligem B-Zell-Lymphom befindet; BMS-986249, ein CTLA-4-Probody-Therapeutikum, das sich in klinischen Studien der Phase I/II zur Behandlung von metastasierendem Melanom befindet, und BMS-986288, ein Anti-CTLA-4-Probody-Therapeutikum, das sich in klinischen Studien der Phase I zur Behandlung von soliden Tumoren befindet. Darüber hinaus entwickelt das Unternehmen CX-2043, ein bedingt aktiviertes ADC, das auf das Adhäsionsmolekül epithelialer Zellen abzielt, sowie CX-904, einen bedingt aktivierten epidermalen Wachstumsfaktor-Rezeptor für die Behandlung solider Tumore. Das Unternehmen unterhält strategische Kooperationen mit AbbVie Ireland Unlimited Company, Amgen, Inc, Bristol-Myers Squibb Company, ImmunoGen, Inc, Pfizer Inc und Astellas Pharma Inc. zur Entwicklung von Probody-Therapeutika. CytomX Therapeutics, Inc. wurde im Jahr 2008 gegründet und hat seinen Hauptsitz in South San Francisco, Kalifornien.

Nome	CytomX Therapeutics
CEO	Sean A. McCarthy
Sede	South San Francisco, ca EUA
Site	cytomx.com
Setor	Materiais básicos
Indústria	Produtos químicos
Entrada em bolsa	13/07/2021
Colaboradores	69